Calcium Signaling Identified as Exploitable Target in Addressing Drug Resistance to Non-Hodgkin Lymphoma Treatment

Gene expression profiling and other analyses conducted by Rutgers Cancer Institute of New Jersey researchers and colleagues examining drug resistance to a common antibody therapy for non-Hodgkin lymphoma have identified calcium signaling as a novel and exploitable target in overcoming this treatment obstacle. Results are being presented at the American Society of Hematology Annual Meeting.

Read more